Master advanced skills in regulatory communications with a focus on strategy, storytelling, and executive presence. This program combines live virtual sessions and practical exercises, empowering ...

Tivic Health Systems, Inc. is a biotechnology company developing immunotherapeutic approaches to modulating immune responses. In the past year, the company has shifted its focus to drug development ...

Broadband industry leader Zenita Henderson to align marketing, sales, and partner programs, accelerating AMT’s role in nationwide broadband expansion DEERFIELD ...

These programs include a high-resolution LiDAR survey to refine structural interpretation and identify subtle topographic and alteration features, a drone-based magnetic survey designed to map ...

Carlos and Malú Alvarez have committed a $20 million gift to UT San Antonio’s College of Business. The gift from the Alvarez family is the first of its kind in the university’s history and will be ...

There will be an ATL Airport hiring event at Riverside Epi Center in Austell, Ga. on April 18 from 9 a.m. to 2 p.m. This is the first of many hiring events for Hartsfield-Jackson Atlanta International ...

The company’s portfolio includes two programs: OKI-345 for breast cancer and OKI-355 for vascular anomalies. OnKure plans to submit Investigational New Drug applications to the U.S. Food and Drug ...

A new year brings a fresh Fierce Biotech Fundraising Tracker designed to record the significant amount of venture capital that flows into biopharma. We’re keeping the same guidelines used for last ...

Kupando raised an additional €10 million in Series A financing, bringing the total Series A funding to €23 million. Investment again led by Remiges Ventures, co-led by LifeCare Partners, with ...

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ ...

-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead Intends to Enter into a Strategic ...